Testosterone is the primary androgenic hormone in humans, playing a role not only in the regulation of the reproductive, metabolic, cardiovascular, nervous, skeletal and immune systems. Current understanding of testosterone biochemistry has expanded significantly: from the classical view of its role in reproductive function to the concept of a pleiotropic hormone with multi-level mechanisms of action. The aim of this study was to analyse current scientific publications on the key biochemical mechanisms of testosterone’s action and to assess its impact on the human body. This study analysed data from PubMed/MEDLINE, Scopus and Web of Science, as well as the results of randomised controlled trials, meta-analyses and reviews published primarily between 2016 and 2026. It summarises current data on testosterone biosynthesis, regulation of the hypothalamic-pituitary-gonadal axis, and the roles of SHBG and the hormone’s active metabolites dihydrotestosterone and oestradiol. It has been established that the biological effects of testosterone are mediated through genomic and non-genomic mechanisms. The genomic pathway is mediated by the intracellular androgen receptor and the regulation of target gene transcription. Non-genomic effects are associated with the activation of the membrane receptors GPRC6A and ZIP9, and the intracellular signalling cascades PI3K/Akt, ERK1/2 and PKC. It has been shown that the same concentration of testosterone can cause different effects depending on SHBG levels, steroidogenesis enzyme activity, androgen receptor variants and associated metabolic states. The metabolic effects of testosterone on insulin sensitivity, obesity, and bone and muscle metabolism are analysed in detail. Particular attention is paid to the findings of the T4DM study, in which the use of testosterone in combination with lifestyle modifications reduced the risk of developing type 2 diabetes by 40%. Current data on the effects of testosterone on the cardiovascular system, the central nervous system, the immune response and prostate health are presented. The TRAVERSE study demonstrated no increased risk of major cardiovascular events with testosterone replacement therapy, although certain adverse events occurred more frequently in the testosterone group. The data confirm that testosterone is a complex pleiotropic hormone with a multi-level regulatory system. Despite significant progress in studying its biochemistry, questions regarding the long-term safety of testosterone replacement therapy, the personalisation of treatment, and the standardisation of the diagnosis of androgen deficiency remain relevant.